50800-92-5

Usage

Uses

2-(4-Methoxyphenoxy)ethylamine can be used electrolyte for batteries.

InChI:InChI=1/C9H13NO2/c1-11-8-2-4-9(5-3-8)12-7-6-10/h2-5H,6-7,10H2,1H3

Upstream product

• 22921-76-2 1-(2-bromoethoxy)-4-methoxybenzene 
• 1074-82-4 potassium phtalimide 
• 22446-12-4 2-(4-methoxyphenoxy)acetonitrile 
• 30893-64-2 2-(4-methoxyphenoxy)acetamide 
• 696-62-8 para-iodoanisole 
• 141-43-5 ethanolamine 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 150-76-5 4-methoxy-phenol 
• 321432-17-1 2-[2-(4-methoxyphenoxy)ethyl]-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 65034-74-4 8-Benzyloxy-5-{2-hydroxy-3-[2-(4-methoxy-phenoxy)-ethylamino]-propoxy}-3,4-dihydro-1H-quinolin-2-one 
• 917108-64-6 4-methoxy-2-{(1-(2-[4-methoxypheoxy]ethyl)aminocarbonyl)cyclopentylmethyl}butyric acid tert-butyl ester 
• 65008-59-5 8-Hydroxy-5-{2-hydroxy-3-[2-(4-methoxy-phenoxy)-ethylamino]-propoxy}-3,4-dihydro-1H-quinolin-2-one; hydrochloride 
• 1220748-12-8 C₂₅H₂₇NO₄ 
• 1616730-27-8 (E)-methyl 3-[2-(4-methoxyphenoxy)ethylamino]acrylate 
• 1616730-56-3 (Z)-methyl 3-[2-(4-methoxyphenoxy)ethylamino]acrylate 

Relevant academic research and scientific papers

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

N-arylation method in aqueous phase system with substituted quinoline or isoquinoyl hydrazide pyridine-N-oxide as ligand

The invention relates to an N-arylation method in an aqueous phase system with substituted quinoline or isoquinoyl hydrazide pyridine-N-oxide as a ligand. The N-arylation method in the aqueous phase system with the substituted quinoline or isoquinoyl hydrazide pyridine-N-oxide as the ligand comprises the following steps of: adding a catalyst, the ligand, a raw material, alkali, a phase transferring catalyst and a solvent into a reactor, heating and stirring, after the reaction is ended, separating and purifying a reaction solution to obtain an N-arylation product, wherein the raw material is aryl halide and a nitrogen-containing nucleophilic reagent, the solvent is a mixed solution of water and ethanol, and the catalyst is metal copper, or a copper oxide, or monovalent copper salt, or bivalent copper salt. The N-arylation method in the aqueous phase system with substituted quinoline or isoquinoyl hydrazide pyridine-N-oxide as the ligand has the characteristics of simplicity in operation, wide substrate application range, simplicity and easiness in separating products, high yield, economical process, environmental protection and the like.

Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents

A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors

Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b]pyrimido[5,4-f]azepine and two alkyl{3-/4-[1-hydroxy-2-(4-arylpiperazin-1-yl)ethyl]phenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands.

Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents

A series of imidazo[1,2-a]pyridine carboxamides (IPAs) bearing an N-(2-phenoxyethyl) moiety was designed and synthesized as new antitubercular agents. Seven 2,6-dimethyl IPAs demonstrated excellent in vitro activity (MIC: 0.025-0.054 μg/mL) against the drug susceptive H37Rv strain and two clinically isolated multidrug-resistant Mycobacterium tuberculosisstrains. Compound 10j displayed acceptable safety and pharmacokinetic properties, opening a new direction for further development.

SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS

Described herein are certain steroid derivative compounds, for example of formula (I): wherein X1, X2, X3 L, and Ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions to specifically target glucocorticoid action, and the use of such compounds and compositions in the treatment of acute and chronic inflammatory conditions, in particular rheumatoid arthritis, haematological and other malignancies, and for causing immunosuppression in the prevention or treatment of transplant rejection, as well as methods of preparing such compounds.

Antitumour indolequinones: Synthesis and activity against human pancreatic cancer cells

An important determinant of the growth inhibitory activity of indolequinones against pancreatic cancer cells is substitution on the 2-position with 2-unsubstituted derivatives being markedly more potent. A series of indolequinones bearing a range of subst

Discovery of a new series of 5-HT1A receptor agonists

Starting from compounds previously identified as α1-adrenoceptor antagonists that were also found to bind to the 5-HT1A receptor, in an attempt to separate the two activities, a new series of 5-HT1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT1A/α1 = 151) and good agonist potency (pD2 = 7.82; Emax = 76), was found to be the most interesting.

Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors

A series of phenoxyalkyl and phenylthioalkyl amides were prepared as melatoninergic ligands. Modulation of affinity of the newly synthesized compound by applying SARs around the terminal amide moiety, the alkyl chain, and the methoxy group on the aromatic ring provides compounds with nanomolar affinity for both melatonin receptor subtypes. Affinity towards MT1 and MT2 receptors were modulated also exploiting chirality. The investigation of intrinsic activity revealed that all the tested compounds behave as full or partial agonists.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder

A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P1′ and P2′ regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study.